- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 510764, 7 pages
Melatonin Levels in Serum and Ascitic Fluid of Patients with Hepatic Encephalopathy
1Department of Gastroenterology, Medical University of Lodz, 1 Haller’s Square, 90-647 Lodz, Poland
2Department of Neuroendocrinology, Medical University of Lodz, 1/3 Sterlinga street, 91-425 Lodz, Poland
3Department of Molecular Genetics, University of Lodz, 141/143 Pomorska street, 90-237 Lodz, Poland
Received 16 August 2012; Accepted 4 December 2012
Academic Editor: Paolo Gionchetti
Copyright © 2012 Cezary Chojnacki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. F. Butterworth, “The neurobiology of hepatic encephalopathy,” Seminars in Liver Disease, vol. 16, no. 3, pp. 235–244, 1996.
- K. Weissenborn, J. C. Ennen, H. Schomerus, N. Rückert, and H. Hecker, “Neuropsychological characterization of hepatic encephalopathy,” Journal of Hepatology, vol. 34, no. 5, pp. 768–773, 2001.
- M. Ortiz, J. Córdoba, C. Jacas, M. Flavià, R. Esteban, and J. Guardia, “Neuropsychological abnormalities in cirrhosis include learning impairment,” Journal of Hepatology, vol. 44, no. 1, pp. 104–110, 2006.
- Y. F. Xiong, Q. Chen, J. Chen, J. Zhou, and H. X. Wang, “Melatonin reduces the impairment of axonal transport and axonopathy induced by calyculin A,” Journal of Pineal Research, vol. 50, no. 3, pp. 319–327, 2011.
- N. K. Singhal, G. Srivastava, D. K. Patel, S. K. Jain, and M. P. Singh, “Melatonin or silymarin reduces maneb- and paraquat-induced Parkinsons disease phenotype in the mouse,” Journal of Pineal Research, vol. 50, no. 2, pp. 97–109, 2011.
- J. H. Stehle, A. Saade, O. Rawashdeh et al., “A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases,” Journal of Pineal Research, vol. 51, no. 1, pp. 17–43, 2011.
- R. J. Reiter and D. X. Tan, “What constitutes a physiological concentration of melatonin?” Journal of Pineal Research, vol. 34, no. 1, pp. 79–80, 2003.
- C. Venegas, J. A. García, G. Escames, et al., “Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations,” Journal of Pineal Research, vol. 52, no. 2, pp. 217–227, 2012.
- D. X. Tan, L. C. Manchester, E. Sanchez-Barcelo, M. D. Mediavilla, and R. J. Reiter, “Significance of high levels of endogenous melatonin in mammalian cerebrospinal fluid and in the central nervous system,” Current Neuropharmacology, vol. 8, no. 3, pp. 162–167, 2010.
- N. T. Raikhlin and I. M. Kvetnoy, “Melatonin and enterochromaffin cells,” Acta Histochemica, vol. 55, no. 1, pp. 19–24, 1976.
- G. Huether, B. Poeggeler, A. Reimer, and A. George, “Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract,” Life Sciences, vol. 51, no. 12, pp. 945–953, 1992.
- G. A. Bubenik, “Gastrointestinal melatonin: localization, function, and clinical relevance,” Digestive Diseases and Sciences, vol. 47, no. 10, pp. 2336–2348, 2002.
- P. Gibson, J. H. Gill, P. A. Khan et al., “Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development,” Molecular Cancer Therapeutics, vol. 2, no. 6, pp. 527–534, 2003.
- I. M. Kvetnoy, I. E. Ingel, T. V. Kvetnaia et al., “Gastrointestinal melatonin: cellular identification and biological role,” Neuroendocrinology Letters, vol. 23, no. 2, pp. 121–132, 2002.
- R. J. Reiter, D. X. Tan, J. C. Mayo, R. M. Sainz, J. Leon, and D. Bandyopadhyay, “Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract,” Journal of Physiology and Pharmacology, vol. 54, pp. 113–125, 2003.
- G. A. Bubenik, S. F. Pang, J. R. Cockshut et al., “Circadian variation of portal, arterial and venous blood levels of melatonin in pigs and its relationship to food intake and sleep,” Journal of Pineal Research, vol. 28, no. 1, pp. 9–15, 2000.
- E. A. Lane and H. B. Noss, “Pharmacokinetics of melatonin in man: first pass hepatic metabolism,” Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 6, pp. 1214–1216, 1985.
- G. Facciolá, M. Hidestrand, C. von Bahr, and G. Tybring, “Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes,” European Journal of Clinical Pharmacology, vol. 56, no. 12, pp. 881–888, 2001.
- X. Ma, J. R. Idle, K. W. Krausz, and F. J. Gonzalez, “Metabolism of melatonin by human cytochromes P450,” Drug Metabolism and Disposition, vol. 33, no. 4, pp. 489–494, 2005.
- D. X. Tan, L. C. Manchester, R. J. Reiter, W. Qi, M. A. Hanes, and N. J. Farley, “High physiological levels of melatonin in the bile of mammals,” Life Sciences, vol. 65, no. 23, pp. 2523–2529, 1999.
- M. Messner, G. Huether, T. Lorf, G. Ramadori, and H. Schwörer, “Presence of melatonin in the human hepatobiliary-gastrointestinal tract,” Life Sciences, vol. 69, no. 5, pp. 543–551, 2001.
- S. Aust, T. Thalhammer, S. Humpeler et al., “The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia,” Journal of Pineal Research, vol. 36, no. 1, pp. 43–48, 2004.
- A. Ardizzi, G. Grugni, G. Saglietti, and F. Morabito, “Circadian rhythm of melatonin (aMT) in liver cirrhosis,” Minerva Medica, vol. 89, no. 1-2, pp. 1–4, 1998.
- S. Montagnese, B. Middleton, A. R. Mani, D. J. Skene, and M. Y. Morgan, “On the origin and the consequences of circadian abnormalities in patients with cirrhosis,” American Journal of Gastroenterology, vol. 105, no. 8, pp. 1773–1781, 2010.
- P. E. Steindl, P. Ferenci, and W. Marktl, “Impaired hepatic catabolism of melatonin in cirrhosis,” Annals of Internal Medicine, vol. 127, no. 6, p. 494, 1997.
- P. C. Zee, R. Mehta, F. W. Turek, and A. T. Blei, “Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats,” Brain Research, vol. 560, no. 1-2, pp. 17–22, 1991.
- D. L. Coy, R. Mehta, P. Zee, F. Salchli, F. W. Turek, and A. T. Blei, “Portal-systemic shunting and the disruption of circadian locomotor activity in the rat,” Gastroenterology, vol. 103, no. 1, pp. 222–228, 1992.
- B. Finn, V. Shah, and J. Gottstein, “Neomycin improves a disrupted circadian rhythm in rats after portacaval anastomosis,” Hepatogastroenterolgy, no. 33, 1993.
- J. Ducis, “Effect of ammonia and R05-4864 on melatonin release in pineal,” Journal of Neurochemistry, vol. 62, article A-37, 1994.
- P. E. Steindl, B. Finn, B. Bendok, S. Rothke, P. C. Zee, and A. T. Blei, “Disruption of the diurnal rhythm of plasma melatonin in cirrhosis,” Annals of Internal Medicine, vol. 123, no. 4, pp. 274–277, 1995.
- A. J. Lewy, S. Ahmed, J. M. Latham Jackson, and R. L. Sack, “Melatonin shifts human circadian rhythms according to a phase-response curve,” Chronobiology International, vol. 9, no. 5, pp. 380–392, 1992.
- K. Celinski, P. C. Konturek, M. Slomka et al., “Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan,” Journal of Pineal Research, vol. 46, no. 4, pp. 408–414, 2009.
- A. Suman, D. S. Barnes, N. N. Zein, G. N. Levinthal, J. T. Connor, and W. D. Carey, “Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores,” Clinical Gastroenterology and Hepatology, vol. 2, no. 8, pp. 719–723, 2004.
- S. Montagnese, P. Amodio, and M. Y. Morgan, “Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach,” Metabolic Brain Disease, vol. 19, no. 3-4, pp. 281–312, 2004.
- P. Ferenci, A. Lockwood, K. Mullen, R. Tarter, K. Weissenborn, and A. T. Blei, “Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998,” Hepatology, vol. 35, no. 3, pp. 716–721, 2002.
- D. X. Tan, L. D. Chen, B. Poeggeler, et al., “Melatonin: a potent endogenous hydroxyl radical scavenger,” Endocrine Journal, vol. 1, pp. 57–60, 1993.
- C. Rodriguez, J. C. Mayo, R. M. Sainz et al., “Regulation of antioxidant enzymes: a significant role for melatonin,” Journal of Pineal Research, vol. 36, no. 1, pp. 1–9, 2004.
- A. Galano, D. X. Tan, and R. J. Reiter, “Melatonin as a natural ally against oxidative stress: a physicochemical examination,” Journal of Pineal Research, vol. 51, no. 1, pp. 1–16, 2011.
- M. E. Letelier, J. Jara-Sandoval, A. Molina-Berríos, M. Faúndez, P. Aracena-Parks, and F. Aguilera, “Melatonin protects the cytochrome P450 system through a novel antioxidant mechanism,” Chemico-Biological Interactions, vol. 185, no. 3, pp. 208–214, 2010.
- C. Castillo, V. Salazar, C. Ariznavarreta, E. Vara, and J. A. F. Tresguerres, “Effect of melatonin administration on parameters related to oxidative damage in hepatocytes isolated from old Wistar rats,” Journal of Pineal Research, vol. 38, no. 4, pp. 240–246, 2005.
- M. Koc, S. Taysi, M. E. Buyukokuroglu, and N. Bakan, “Melatonin protects rat liver against irradiation-induced oxidative injury,” Journal of Radiation Research, vol. 44, no. 3, pp. 211–215, 2003.
- W. M. Daniels, R. J. Reiter, D. Melchiorri, E. Sewerynek, M. I. Pablos, and G. G. Ortiz, “Melatonin counteracts lipid peroxidation induced by carbon tetrachloride but does not restore glucose-6 phosphatase activity,” Journal of Pineal Research, vol. 19, no. 1, pp. 1–6, 1995.
- E. Sewerynek, R. J. Reiter, D. Melchiorri, G. G. Ortiz, and A. Lewinski, “Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin,” Hepato-Gastroenterology, vol. 43, no. 10, pp. 898–905, 1996.
- N. Bülbüller, Z. Cetinkaya, M. A. Akkus, et al., “The effects of melatonin and prostaglandin E1 analogue on experimental hepatic ischaemia reperfusion damage,” International Journal of Clinical Practice, vol. 57, pp. 857–860, 2003.
- M. Vairetti, A. Ferrigno, R. Bertone et al., “Exogenous melatonin enhances bile flow and ATP levels after cold storage and reperfusion in rat liver: implications for liver transplantation,” Journal of Pineal Research, vol. 38, no. 4, pp. 223–230, 2005.
- M. A. Zaoualí, R. J. Reiter, S. Padrissa-Altés et al., “Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury,” Journal of Pineal Research, vol. 50, no. 2, pp. 213–221, 2011.
- V. Tahan, R. Ozaras, B. Canbakan et al., “Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats,” Journal of Pineal Research, vol. 37, no. 2, pp. 78–84, 2004.
- I. Túnez, M. C. Muñoz, M. A. Villavicencio et al., “Hepato- and neurotoxicity induced by thioacetamide: protective effects of melatonin and dimethylsulfoxide,” Pharmacological Research, vol. 52, no. 3, pp. 223–228, 2005.
- A. Cruz, F. J. Padillo, E. Torres et al., “Melatonin prevents experimental liver cirrhosis induced by thioacetamide in rats,” Journal of Pineal Research, vol. 39, no. 2, pp. 143–150, 2005.
- H. Wang, W. Wei, N. P. Wang et al., “Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress,” Life Sciences, vol. 77, no. 15, pp. 1902–1915, 2005.
- X. Chen, C. Zhang, M. Zhao, et al., “Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice,” Journal of Pineal Research, vol. 51, pp. 416–425, 2011.
- Y. Ohta, M. Kongo, and T. Kishikawa, “Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation,” Journal of Pineal Research, vol. 34, no. 2, pp. 119–126, 2003.
- F. J. Padillo, A. Cruz, C. Navarrete et al., “Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis,” Free Radical Research, vol. 38, no. 7, pp. 697–704, 2004.
- M. Esrefoglu, M. Gül, M. H. Emre, A. Polat, and M. A. Selimoglu, “Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats,” World Journal of Gastroenterology, vol. 11, no. 13, pp. 1951–1956, 2005.
- A. Barlas, H. Çevik, S. Arbak et al., “Melatonin protects against pancreaticobiliary inflammation and associated remote organ injury in rats: role of neutrophils,” Journal of Pineal Research, vol. 37, no. 4, pp. 267–275, 2004.
- H. Wang, W. Wei, Y. X. Shen et al., “Protective effect of melatonin against liver injury in mice induced by Bacillus Calmette-Guerin plus lipopolysaccharide,” World Journal of Gastroenterology, vol. 10, no. 18, pp. 2690–2696, 2004.
- R. J. Reiter, S. D. Paredes, L. C. Manchester, and D. X. Tan, “Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin,” Critical Reviews in Biochemistry and Molecular Biology, vol. 44, no. 4, pp. 175–200, 2009.
- E. Sahna, H. Parlakpinar, N. Vardi, Y. Ciǧremis, and A. Acet, “Efficacy of melatonin as protectant against oxidative stress and structural changes in liver tissue in pinealectomized rats,” Acta Histochemica, vol. 106, no. 5, pp. 331–336, 2004.
- A. M. Mathes, “Hepatoprotective actions of melatonin: possible mediation by melatonin receptors,” World Journal of Gastroenterology, vol. 16, no. 48, pp. 6087–6097, 2010.
- R. T. Hong, J. M. Xu, and Q. Mei, “Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats,” World Journal of Gastroenterology, vol. 15, no. 12, pp. 1452–1458, 2009.
- G. Tahan, H. Akin, F. Aydogan et al., “Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats,” Canadian Journal of Surgery, vol. 53, no. 5, pp. 313–318, 2010.
- M. Pan, Y. L. Song, J. M. Xu, and H. Z. Gan, “Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats,” Journal of Pineal Research, vol. 41, no. 1, pp. 79–84, 2006.
- H. Cichoz-Lach, K. Celinski, P. C. Konturek, et al., “The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis,” Journal of Physiology and Pharmacology, vol. 61, pp. 577–5780, 2010.
- M. Gonciarz, Z. Gonciarz, W. Bielanski et al., “The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin,” Journal of Physiology and Pharmacology, vol. 61, no. 6, pp. 705–710, 2010.
- A. Nickkholgh, H. Schneider, M. Sobirey et al., “The use of high-dose melatonin in liver resection is safe: first clinical experience,” Journal of Pineal Research, vol. 50, no. 4, pp. 381–388, 2011.
- H. Iguchi, K. I. Kato, and H. Ibayashi, “Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis,” Journal of Clinical Endocrinology and Metabolism, vol. 54, no. 5, pp. 1025–1027, 1982.
- D. Velissaris, V. Karamouzos, P. Polychronopoulos, and M. Karanikolas, “Chronotypology and melatonin alterations in minimal hepatic encephalopathy,” Journal of Circadian Rhythms, vol. 7, article 6, 2009.
- P. E. Steindl, B. Finn, B. Bendok, et al., “Changes in the 24-hour rhythm of plasma melatonin in patients with liver cirrhosis—relation to sleep architecture,” Wien Klin Wochenschr, vol. 109, pp. 741–746, 1997.
- J. Córdoba, J. Cabrera, L. Lataif, P. Penev, P. Zee, and A. T. Blei, “High prevalence of sleep disturbance in cirrhosis,” Hepatology, vol. 27, no. 2, pp. 339–345, 1998.
- S. Montagnese, B. Middleton, A. R. Mani, D. J. Skene, and M. Y. Morgan, “Sleep and circadian abnormalities in patients with cirrhosis: features of delayed sleep phase syndrome?” Metabolic Brain Disease, vol. 24, no. 3, pp. 427–439, 2009.